A ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, its preparation method, and its application.

The ROS/pH dual-responsive quercetin self-framework nanomedicine constructed using an oxalyl chloride-responsive framework solves the problems of water solubility and bioavailability of quercetin in the treatment of osteoarthritis. It achieves responsive drug release and ROS consumption in response to the pathological microenvironment of osteoarthritis, effectively reducing inflammatory response, maintaining extracellular matrix homeostasis of chondrocytes, and delaying the progression of osteoarthritis.

CN123101697APending Publication Date: 2026-11-17南昌大学第一附属医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611377608.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-07
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing quercetin treatments for osteoarthritis suffer from poor water solubility, low bioavailability, insufficient local effective drug concentration, and lack of responsive release to the pathological microenvironment. Furthermore, traditional nanocarrier systems are complex to prepare and have limited drug loading capacity.

Method used

A ROS/pH dual-responsive quercetin self-framework nanomedicine was constructed using an oxalyl chloride-responsive framework. The oxalate ester linkage structure was formed by the esterification reaction of oxalyl chloride with quercetin and polyethylene glycol, thus constructing the quercetin self-framework nanomedicine to achieve responsive release and ROS consumption in response to the pathological microenvironment of osteoarthritis.

Benefits of technology

It improves the water dispersibility and stability of quercetin, enabling responsive drug release in the pathological microenvironment of osteoarthritis, reducing ROS accumulation and inflammatory response in chondrocytes, maintaining extracellular matrix homeostasis in chondrocytes, and delaying the progression of osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101697A_ABST
    Figure CN123101697A_ABST
Patent Text Reader

Abstract

This invention discloses a ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, its preparation method, and its application, belonging to the field of pharmaceutical technology. The preparation method of the nanomedicine of this invention includes the following steps: adding quercetin and a hydroxyl-containing hydrophilic polymer to a solvent, dissolving them, adding a tertiary amine organic base, then placing the mixture under an inert atmosphere and low temperature conditions, followed by the addition of oxalyl chloride, causing the oxalyl chloride to undergo an esterification reaction with quercetin and the hydroxyl groups in the hydroxyl-containing hydrophilic polymer, forming a reaction product with an oxalate ester linkage structure; after the reaction, purification and drying are performed to obtain the nanomedicine. The nanomedicine of this invention can undergo responsive degradation in the high ROS and acidic microenvironment of osteoarthritis, promoting quercetin release, while simultaneously utilizing the oxalate ester structure degradation process to consume ROS, achieving a synergistic effect of pathological microenvironment response, ROS clearance, quercetin release, and inhibition of chondrocyte ferroptosis, thereby reducing inflammatory responses and chondrocyte damage, maintaining extracellular matrix homeostasis of chondrocytes, and delaying the progression of osteoarthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, and in particular to a ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, its preparation method, and its application. Background Technology

[0002] Osteoarthritis (OA) is a common chronic degenerative joint disease, mainly characterized by articular cartilage degeneration, extracellular matrix degradation, and abnormal subchondral bone remodeling. Current clinical treatment focuses primarily on analgesia, anti-inflammation, and improving joint function, lacking effective treatments to slow disease progression. Osteoarthritis is characterized by a chronic inflammatory and oxidative stress microenvironment; excessive reactive oxygen species (ROS) can promote lipid peroxidation, mitochondrial damage, and chondrocyte ferroptosis, further accelerating cartilage matrix degradation. Therefore, responsive interventions targeting the high ROS and other pathological microenvironments of osteoarthritis are crucial for improving treatment outcomes.

[0003] Quercetin (Que) is a natural flavonoid compound with anti-inflammatory, antioxidant, and chondroprotective effects, and it has the potential to inhibit lipid peroxidation and chondrocyte ferroptosis. However, quercetin suffers from poor water solubility, low bioavailability, and insufficient local effective utilization, limiting its application in the treatment of osteoarthritis. While existing nanocarriers such as PLGA and metal-organic frameworks can improve quercetin delivery, they still suffer from drawbacks such as complex preparation systems, high proportion of exogenous carriers, limited drug loading, and lack of active response to the pathological microenvironment of osteoarthritis. Therefore, there is an urgent need to construct a quercetin self-delivery system that combines high drug loading, good water dispersibility, and microenvironment responsiveness to overcome the problems of poor water solubility, low bioavailability, insufficient local effective drug concentration, and lack of responsive release to the pathological microenvironment of osteoarthritis in existing quercetin treatments. Simultaneously, it should overcome the relatively complex preparation, limited drug loading ratio, and carrier metabolism issues associated with traditional exogenous nanocarrier systems such as PLGA and MOF. Summary of the Invention

[0004] The purpose of this invention is to provide a ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, its preparation method, and its application, in order to solve the problems existing in the prior art.

[0005] To achieve the above objectives, the present invention provides the following solution: One of the technical solutions of the present invention is a method for preparing a ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, comprising the following steps: Quercetin (Que) and a hydroxyl-containing hydrophilic polymer were added to a solvent and dissolved. A tertiary amine organic base was then added, and the mixture was placed under an inert atmosphere and low temperature. Oxaloyl chloride was then added, causing the oxaloyl chloride to undergo an esterification reaction with the hydroxyl groups in quercetin and the hydroxyl-containing hydrophilic polymer, forming a reaction product with an oxalate ester linkage structure. After the reaction was completed, the product was purified and dried to obtain the ROS / pH dual-responsive quercetin self-framework nanomedicine (i.e., OQP NPs).

[0006] Oxaloyl chloride can not only serve as a linking unit between quercetin and polyethylene glycol, but also form oxalate ester structures that are broken by acidic environments and ROS. Therefore, the resulting nanomedicine uses quercetin itself as an important structural and pharmacological functional component of the nanosystem, forming a responsive self-framework structure through oxalloyl chloride linkage, which is different from the delivery mode of physically encapsulating quercetin in traditional nanocarriers.

[0007] Preferably, the hydroxyl-containing hydrophilic polymer includes polyethylene glycol (PEG).

[0008] Polyethylene glycol can improve the water dispersibility and stability of ROS / pH dual-responsive quercetin self-framework nanomedicines (i.e., nanosystems).

[0009] Preferably, the tertiary amine organic base includes triethylamine, which acts as an acid-binding agent or a reaction promoter.

[0010] Preferably, per 1 mmol of quercetin, the amount of the hydroxyl-containing hydrophilic polymer is 180–260 mg, the amount of the solvent is 20–40 mL, the amount of the tertiary amine organic base is 1–3 mL, and the amount of oxaloyl chloride is 0.08–0.18 mL.

[0011] More preferably, the amounts of quercetin, the hydroxyl-containing hydrophilic polymer, the solvent, the tertiary amine organic base, and oxalyl chloride are 302 mg, 220 mg, 30 mL, 2 mL, and 0.12 mL, respectively.

[0012] Preferably, the inert atmosphere includes a nitrogen atmosphere.

[0013] Preferably, the esterification reaction takes 8 to 24 hours; more preferably 10 to 16 hours; and even more preferably 12 hours.

[0014] Preferably, the purification includes placing the reaction product in a dialysis bag with a molecular weight cutoff of 2000-8000 Da, and performing dialysis purification using deionized water and ethanol as the dialysis medium.

[0015] More preferably, the molecular weight cutoff of the dialysis bag is 3000-5000 Da; even more preferably, it is 3500 Da.

[0016] Preferably, the dialysis purification time is 24–72 h; more preferably 36–60 h; and even more preferably 48 h.

[0017] More preferably, the solvent includes tetrahydrofuran (THF).

[0018] This invention utilizes the reaction between oxalyl chloride and the phenolic hydroxyl groups of quercetin to construct a ROS / pH dual-responsive oxalate ester linkage structure, and introduces polyethylene glycol to form a quercetin self-framework nanomedicine system (OQP NPs). Unlike the traditional strategy of "drug encapsulation on exogenous nanocarriers," this invention uses quercetin itself as a crucial structural and functional component of the nanosystem, eliminating the need for traditional carriers such as PLGA and MOF. This achieves higher drug loading while improving the water dispersibility and stability of quercetin. The formed oxalate ester structure can simultaneously respond to the high ROS and acidic microenvironment of osteoarthritis lesions. It remains relatively stable under normal physiological conditions, but undergoes responsive breakage in the pathological microenvironment, promoting quercetin release and achieving microenvironment-triggered, sustained drug release. Simultaneously, the oxalate ester structure can consume some ROS during ROS-mediated degradation, working together with the released quercetin to exert an antioxidant effect, thus forming a synergistic therapeutic mode of "ROS / pH dual response - nanostructure dissociation - ROS consumption - quercetin release." Furthermore, the synergistic effect of the structure of this nanosystem and the pharmacological activity of quercetin can reduce ROS accumulation and Fe in chondrocytes. 2+ It can overload and inhibit lipid peroxidation, and restore the NRF2 / HO-1 and SLC7A11 / GPX4 antioxidant defense system, maintain mitochondrial structure and membrane potential stability, thereby reducing oxidative stress and inhibiting chondrocyte ferroptosis, and further reducing inflammatory response and extracellular matrix degradation, thus achieving comprehensive intervention for osteoarthritis cartilage degeneration.

[0019] In addition, OQP NPs can increase COL2A1 expression and decrease MMP13 and iNOS expression, reduce inflammatory response and chondrocyte extracellular matrix degradation, thereby maintaining cartilage matrix homeostasis; in a DMM-induced mouse osteoarthritis model, they can alleviate articular cartilage degeneration, proteoglycan loss and subchondral bone microstructure damage.

[0020] This invention integrates multiple functions, including carrier simplification, ROS / pH dual-response release, material self-ROS consumption, and quercetin anti-ferroptosis therapy, providing a new technical solution for microenvironment-responsive nanotherapy of osteoarthritis.

[0021] The second technical solution of the present invention: a ROS / pH dual-responsive quercetin self-framework nanomedicine prepared by the above preparation method.

[0022] The third technical solution of the present invention: the application of the above-mentioned ROS / pH dual-responsive quercetin self-framework nanomedicine as a drug for the prevention and / or treatment of osteoarthritis.

[0023] The present invention discloses the following technical effects: (1) The ROS / pH dual-responsive quercetin self-framework nanomedicine based on the oxalyl chloride responsive framework of the present invention uses quercetin as the main active and structural component. It forms an oxalate ester linkage structure with ROS / pH responsive characteristics through oxalyl chloride mediation, and introduces polyethylene glycol to improve the water dispersibility and stability of the nanosystem. The quercetin self-framework nanomedicine (OQP NPs) is constructed in one step. This nanomedicine can undergo responsive degradation in the high ROS and acidic microenvironment of osteoarthritis and promote quercetin release. At the same time, it consumes ROS through the degradation process of the oxalate ester structure, realizing the synergistic effect of pathological microenvironment response, ROS clearance, quercetin release and inhibition of chondrocyte ferroptosis, thereby reducing inflammatory response and chondrocyte damage, maintaining the extracellular matrix homeostasis of chondrocytes and delaying the progression of osteoarthritis.

[0024] (2) The method of constructing the ROS / pH dual-response quercetin self-framework nanomedicine based on the oxalyl chloride response framework of the present invention is simple. Quercetin, polyethylene glycol and oxalyl chloride are the main raw materials. The quercetin nanosystem can be constructed in one step without the need for further complex drug loading using traditional exogenous nanocarriers such as PLGA and MOF, which simplifies the preparation process of quercetin nanomedicine.

[0025] (3) This invention achieves self-framed quercetin and high drug loading. This invention uses quercetin itself as an important component of the nanostructure, which avoids a large amount of non-drug carriers occupying the mass ratio of the nanosystem, while achieving a quercetin loading of about 28.3 wt.%, and significantly improves the original water dispersibility and stability of quercetin.

[0026] The nanomedicine of this invention can form stable dispersed nanoparticles in an aqueous medium, with the particles exhibiting a near-spherical structure. Dynamic light scattering analysis showed that the average hydrodynamic particle size of OQP NPs was approximately 145.6 ± 43.2 nm, the PDI was approximately 0.252, and the Zeta potential was approximately -25.2 mV. Transmission electron microscopy revealed that the average particle size was approximately 120 nm, and the nanomedicine exhibited good water dispersibility and stability.

[0027] (4) The nanomedicine of the present invention has the ability to release in response to both ROS and pH microenvironments. The oxalate structure formed by oxalyl chloride can respond to both high ROS and acidic conditions at the same time, so that OQP NPs remain relatively stable under normal conditions, while accelerating structural dissociation and quercetin release in the pathological microenvironment of osteoarthritis, thereby reducing drug release in non-lesion areas and improving the selectivity of the treatment environment.

[0028] The nanomedicine of the present invention exhibits a cumulative quercetin release of approximately 30% within 60 hours at pH 7.4; this can be increased to approximately 55% at pH 5.4; approximately 52% at pH 7.4 with 0.5 mM H2O2; and further increased to approximately 65% ​​under the combined stimulation conditions of pH 5.4 with 0.5 mM H2O2, indicating that the OQP NPs possess significant ROS / pH dual microenvironment response release capabilities.

[0029] (5) The structure of the nanomedicine of the present invention has ROS consumption function. The oxalate responsive framework in the present invention not only serves as the connecting unit of the quercetin nanostructure, but also undergoes responsive degradation and consumes ROS under the action of ROS, and works together with the released quercetin to exert an antioxidant effect, realizing the transformation from simple "drug loading" to "material response and drug therapy synergy".

[0030] (6) The nanomedicine of this invention has both antioxidant and anti-ferroptosis effects. OQP NPs can reduce ROS and Fe 2+ It inhibits the accumulation and lipid peroxidation, restores the NRF2 / HO-1 and SLC7A11 / GPX4 antioxidant defense system, and maintains mitochondrial structure and function, thereby inhibiting ferroptosis in osteoarthritis chondrocytes from multiple aspects.

[0031] (7) The nanomedicine of the present invention has good cartilage protection and biosafety. OQP NPs can inhibit inflammatory response and extracellular matrix degradation, effectively reduce cartilage degeneration and subchondral bone damage in DMM-induced osteoarthritis animal models, while no significant damage to major organs or systemic toxicity was observed, showing good potential for local treatment of osteoarthritis. Attached Figure Description

[0032] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0033] Figure 1 This is a schematic diagram illustrating the preparation and mechanism of action of the OQP NPs of the present invention, wherein A is a schematic diagram of the preparation principle and B is a schematic diagram of the mechanism of action; Figure 2The figure shows the chemical structure and water dispersibility characterization results of the OQP NPs prepared in Example 1 of the present invention. In the figure, A is the Fourier transform infrared spectrum of quercetin, PEG and OQP NPs, B is the ultraviolet-visible absorption spectrum of OQP NPs, and C is the dispersion and long-term stability of OQP NPs in aqueous medium. Figure 3 The images show the drug loading, responsive release, and nanostructure characterization of the OQP NPs prepared in Example 1 of this invention. A represents the standard curve used to determine the quercetin loading in the OQP NPs; B represents the drug release curves of the OQP NPs under pH 5.4, pH 7.4, pH 7.4 + 0.5 mM H2O2, and pH 5.4 + 0.5 mM H2O2 conditions; C represents the dynamic light scattering particle size distribution of the OQP NPs; and D represents the transmission electron microscope image of the OQP NPs. Figure 4 The image shows the cell compatibility evaluation results of OQP NPs prepared in Example 1 of this invention. In the image, A shows the cell viability detection results of CCK-8 cells after treatment with different concentrations of quercetin and OQP NPs for 24 h, B shows the cell viability detection results of CCK-8 cells after treatment with different concentrations of quercetin and OQP NPs for 48 h, C shows the fluorescence staining image of live / dead cells, and D shows the EdU cell proliferation staining image. Figure 5 The figure shows the effect of OQP NPs prepared in Example 1 of this invention on the extracellular matrix homeostasis and inflammatory response of chondrocytes under inflammatory stimulation. In this figure, A and B are the Western blot and quantitative results of COL2A1, MMP13 and iNOS proteins, C is the immunofluorescence detection result of related proteins, and D is the toluidine blue staining result of chondrocytes. Figure 6 The results of the detection of OQP NPs prepared in Example 1 of the present invention in alleviating oxidative stress in chondrocytes are shown in Figure 1. Among them, A is the result of intracellular ROS fluorescence detection, B and C are the results of NRF2 and HO-1 related Western blot detection and quantification, and D is the result of NRF2 nuclear translocation immunofluorescence detection. Figure 7 The results of detecting the inhibition of IL-1β-induced chondrocyte ferroptosis by OQP NPs prepared in Example 1 of this invention are shown; where A is the intracellular Fe detected by FerroOrange. 2+ The fluorescence images are shown in Figure B, which is the fluorescence image of lipid peroxidation detected by BODIPY C11, and Figures C and D are the Western blot and quantitative results of SLC7A11 and GPX4 proteins. Figure 8The results of the detection of the OQP NPs prepared in Example 1 of the present invention to maintain the mitochondrial homeostasis of chondrocytes are shown. Among them, A is the transmission electron microscope image of the ultrastructure of mitochondria in chondrocytes of different treatment groups, and B is the fluorescence image of mitochondrial membrane potential detected by JC-1. Figure 9 The image shows the effect of OQP NPs prepared in Example 1 of this invention on treating DMM-induced osteoarthritis in mice; where A is the Micro-CT three-dimensional reconstruction image of the knee joint of each group of mice, B is the quantitative analysis results of parameters such as subchondral bone BV / TV, Tb.N, and Tb.Sp, and C is the H&E staining and Safranin O / Fixed Green staining image of the mouse knee joint. Figure 10 The results of immunohistochemical detection of articular cartilage-related proteins after OQP NPs prepared in Example 1 of the present invention were used to treat DMM-induced osteoarthritis. Among them, A is the immunohistochemical staining pattern of MMP13, iNOS, COL2A1 and GPX4, and B is the quantitative analysis result of positive staining of the above proteins. Figure 11 This is a histological image of the main organs used in the in vivo biosafety evaluation of OQP NPs prepared in Example 1 of this invention. Figure 12 This is a graph showing the serum biochemical test results in the in vivo biosafety evaluation of OQP NPs of the present invention. Detailed Implementation

[0034] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0035] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0036] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0037] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0038] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0039] It should be noted that any aspects not described in detail in this invention are conventional practices in the field and are not the focus of this invention.

[0040] Example 1 A method for preparing ROS / pH dual-responsive quercetin self-framework nanomedicines (i.e., OQPNPs) based on an oxalyl chloride-responsive framework: (1) Weigh 302 mg (1 mmol) of quercetin (Que) and 220 mg of polyethylene glycol (PEG, 2 kDa), add them together to 30 mL of anhydrous tetrahydrofuran (THF), dissolve them thoroughly and mix them evenly to obtain a quercetin-polyethylene glycol mixed solution.

[0041] (2) Add 2 mL of anhydrous triethylamine to the above mixed solution, then introduce nitrogen gas into the reaction system and place it under ice bath conditions to keep the reaction system at a low temperature.

[0042] (3) Under ice bath and continuous stirring conditions, 0.12 mL of oxalyl chloride was slowly added dropwise to the above reaction system, so that oxalyl chloride reacted with the hydroxyl groups in quercetin and polyethylene glycol molecules respectively to form a polymer system with oxalate linkage structure; after the addition was completed, stirring was continued and the reaction was carried out for 12 hours, so that oxalyl chloride reacted with the hydroxyl groups in quercetin and PEG molecules to form a polymer product with oxalate linkage structure.

[0043] (4) After the reaction is completed, water is added to terminate the reaction. The crude product is placed in a dialysis bag with a molecular weight cutoff of 3500 Da. After the reaction is completed, water is added to terminate the reaction. First, a mixed solution of deionized water and ethanol at a volume ratio of 1:1 is dialyzed for 24 h. Then, deionized water is used to continue dialyzing for 24 h to remove unreacted quercetin, polyethylene glycol, small molecule by-products and residual organic solvents. The total dialyzing time is 48 h.

[0044] (5) After dialysis, the sample was collected and freeze-dried for 24 h to obtain ROS / pH dual-response quercetin self-framework nanomedicine based on oxalyl chloride response framework, namely OQP NPs.

[0045] A schematic diagram illustrating the preparation and mechanism of action of OQP NPs is shown below. Figure 1 Where A is a schematic diagram of the preparation principle and B is a schematic diagram of the mechanism of action. Figure 1 The paper illustrates the formation of OQP NPs from quercetin, PEG, and oxalyl chloride, and their mechanism of action in treating osteoarthritis through antioxidation and inhibition of chondrocyte ferroptosis.

[0046] Example 1 Characterization of the chemical structure, morphology and dispersion properties of OQP NPs: (1) Fourier transform infrared spectroscopy analysis Fourier transform infrared spectroscopy was used to detect the characteristic absorption peaks of quercetin, PEG, and the OQP NPs prepared in Example 1, respectively, to verify the successful synthesis of OQP NPs. The results are shown in [Figure 1]. Figure 2 Figure A.

[0047] from Figure 2 As can be seen from Figure A, OQP NPs are at 1624 cm⁻¹. -1 and 1465 cm -1 Characteristic peaks related to the C=C stretching vibration of the benzene ring of quercetin appear at 2885 cm⁻¹. -1 A CH stretching vibration peak appeared nearby in the PEG. Simultaneously, a peak was observed at 1726 cm⁻¹. -1 A distinct carbonyl C=O characteristic absorption peak appears at 1111 cm⁻¹, and at 1111 cm⁻¹... -1 The presence of CO-related absorption peaks nearby indicates the formation of new ester bond structures in the reaction system. These results demonstrate that oxalyl chloride successfully reacted with quercetin and PEG to form OQP NPs containing oxalate ester linkages.

[0048] (2) Ultraviolet absorption and water dispersibility analysis The spectral characteristics of the OQP NPs prepared in Example 1 were analyzed by ultraviolet-visible spectrophotometry. The results are shown in [Figure number missing]. Figure 2 Figure B.

[0049] from Figure 2 As can be seen in Figure B, OQP NPs have a distinct absorption peak at approximately 365 nm, which is related to the characteristic absorption of quercetin.

[0050] Quercetin and the OQP NPs prepared in Example 1 were dispersed separately in sterile deionized water and placed at 37°C for 90 days. Quercetin showed significant water solubility deficiency, while the OQP NPs formed a uniform and transparent dispersion. The obtained OQP NPs did not show significant precipitation or aggregation after 90 days at 37°C, indicating that the water dispersibility and colloidal stability of quercetin were significantly improved after PEG modification and self-framework nanostructuring. Figure 2 (Figure C).

[0051] Example 2 Drug loading, particle size, morphology, and ROS / pH dual-response release performance of OQP NPs: (1) Determination of quercetin loading The quercetin content in OQP NPs was determined by ultraviolet-visible spectrophotometry. First, seven concentration gradients of quercetin standard solutions were prepared, and the absorbance was measured at 370 nm. A standard curve was then established between quercetin concentration and absorbance. Figure 3 The linear regression equation (A = 0.06292C + 0.04674) is given by Figure A, and the Pearson correlation coefficient (r = 0.9984, R0) is given by Figure A. 2 =0.9968). Subsequently, 5 mg of OQP NPs were accurately weighed, dissolved in 50 mL of the same solvent, and the absorbance was measured at 370 nm. The mass of quercetin in the nanomedicine was calculated according to the standard curve.

[0052] The results showed that the quercetin standard curve had a good linear relationship with a correlation coefficient of 0.9984; the quercetin loading in OQP NPs was approximately 28.3 wt.%, indicating that the self-framework nanosystem could obtain a high proportion of active drug components.

[0053] (2) ROS / pH dual-response drug release analysis To simulate the normal physiological environment and the acidic, high-ROS microenvironment of osteoarthritis lesions, the OQP NPs prepared in Example 1 were placed in the following release systems: A. pH 7.4 PBS; B. pH 5.4 PBS; C. pH 7.4 PBS + 0.5 mM H2O2; D. pH 5.4 PBS + 0.5 mM H2O2.

[0054] Five mg of OQP NPs were placed in a dialysis bag with a molecular weight cutoff of 3500 Da for each group. The bag was continuously shaken, and the release solution was collected at different time points. The quercetin content was then measured. The results are shown below. Figure 3 Figure B.

[0055] from Figure 3 As shown in Figure B, the cumulative release of quercetin within 60 hours is approximately 30% under pH 7.4 conditions; it increases to approximately 55% under pH 5.4 conditions; it is approximately 52% under pH 7.4 + 0.5 mM H2O2 conditions; and the release is highest under the dual stimulation environment of pH 5.4 + 0.5 mM H2O2, with a cumulative release of approximately 65% ​​over 60 hours.

[0056] These results indicate that OQP NPs exhibit good structural stability and sustained release characteristics under normal physiological conditions. Acidic conditions and ROS can both promote the breakage of oxalate ester linkages, with a more pronounced synergistic response effect observed when acidity and ROS coexist. Therefore, OQP NPs can achieve responsive quercetin release in response to the acidic, high-ROS pathological microenvironment of osteoarthritis.

[0057] (3) Characterization of particle size, potential and morphology The hydrodynamic particle size and polydispersity index of the OQP NPs prepared in Example 1 were determined by dynamic light scattering (DLS), and their surface potential was measured by a Zeta potential analyzer. The morphology of the nanoparticles was observed by transmission electron microscopy. The results are shown in the figure. Figure 3 Diagrams C and D.

[0058] from Figure 3 As shown in Figures C and D, the average hydrodynamic particle size of OQP NPs is 145.6 ± 43.2 nm, the PDI is 0.252, and the Zeta potential is approximately -25.2 mV. Transmission electron microscopy reveals that OQP NPs exhibit a regular, near-spherical structure with a relatively smooth surface, and the average particle size measured by TEM is approximately 120 nm.

[0059] The above results indicate that the obtained OQP NPs have a relatively uniform nanoscale structure and good aqueous dispersion stability.

[0060] Example 3 Cell compatibility evaluation of OQP NPs: To evaluate the cell compatibility of the OQP NPs prepared in Example 1, the effects of quercetin (i.e., free quercetin) and OQP NPs on chondrocyte viability and proliferation were assessed using CCK-8 assay, live / dead cell staining, and EdU staining. Chondrocytes were first treated with different concentrations of free quercetin or OQP NPs for 24 h and 48 h, and cell viability was detected using the CCK-8 assay. The results are shown in [Figure number missing]. Figure 4 Figures A and B are shown. Cell viability after treatment with 5 μg / mL free quercetin or OQP NPs for 48 h was evaluated using Calcein-AM / PI live / dead cell staining. Results are shown in Figure A. Figure 4 Figure C. The results of staining cells treated with 5 μg / mL free quercetin or OQP NPs using EdU for 48 h are shown in Figure C. Figure 4 The D diagram.

[0061] from Figure 4As shown in Figures A through D, within the same experimental concentration range, free quercetin exhibited relatively significant cytotoxicity, while cells treated with OQP NPs maintained a high survival rate, indicating that nanotechnology can reduce the cytotoxicity caused by rapid exposure to free quercetin. Further evaluation using Calcein-AM / PI live / dead cell staining revealed that after 48 h of OQP NPs treatment, the field of view was dominated by green live cells, with no significant increase in dead cells. EdU staining results further showed that a large number of EdU-positive cells were still observed in the OQP NPs-treated group, indicating that chondrocytes maintained good proliferative activity after OQP NPs treatment.

[0062] Example of effect 4 The protective effect of OQP NPs (prepared in Example 1) on the extracellular matrix homeostasis of chondrocytes under inflammatory conditions: An in vitro osteoarthritis inflammation model was established by stimulating ATDC5 chondrocytes with IL-1β at a final concentration of 10 ng / mL for 48 h. The experimental groups and treatments were as follows: the normal control group was cultured in an equal volume of standard complete culture medium for 48 h; the IL-1β model group was treated with IL-1β at a final concentration of 10 ng / mL for 48 h; the free quercetin treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and free quercetin at a final concentration of 5 ng / mL for 48 h; and the OQP NPs treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and OQP NPs at a final concentration of 5 ng / mL for 48 h. The expression of cartilage matrix synthesis-related protein COL2A1, matrix degradation protein MMP13, and inflammation-related protein iNOS was detected by Western blot. Changes in the extracellular matrix of chondrocytes were evaluated using immunofluorescence staining and toluidine blue staining. The results are shown in the table below. Figure 5 In the table, A and B are the Western blot and quantitative results of COL2A1, MMP13 and iNOS proteins, C is the immunofluorescence detection result of related proteins, and D is the toluidine blue staining result of chondrocytes.

[0063] from Figure 5 As can be seen, compared with the normal control group, IL-1β stimulation decreased COL2A1 expression, while MMP13 and iNOS expression increased, indicating that inflammatory stimulation led to the inhibition of extracellular matrix synthesis and enhanced matrix degradation in chondrocytes. Treatment with free quercetin improved these changes to some extent, while treatment with OQP NPs resulted in a more significant recovery of COL2A1 expression, and further decreased MMP13 and iNOS expression. Immunofluorescence and toluidine blue staining results were consistent with Western blot results, indicating that OQP NPs have a stronger effect than free quercetin in maintaining extracellular matrix homeostasis and reducing inflammatory responses in chondrocytes.

[0064] Example 5 The regulatory role of OQP NPs in chondrocyte oxidative stress: To evaluate the antioxidant capacity of OQP NPs, intracellular ROS were detected in ATDC5 chondrocytes from different treatment groups. The experimental groups and treatment methods were as follows: the normal control group was cultured in an equal volume of conventional complete culture medium for 48 h; the IL-1β model group was treated with IL-1β at a final concentration of 10 ng / mL for 48 h; the free quercetin treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and free quercetin at a final concentration of 5 ng / mL for 48 h; and the OQP NPs treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and OQP NPs at a final concentration of 5 ng / mL for 48 h. The expression levels of NRF2 and HO-1 antioxidant signaling-related proteins were analyzed and detected. The results are shown in […]. Figure 6 In this table, A represents the intracellular ROS fluorescence detection results, B and C represent the NRF2 and HO-1 related Western blot detection and quantification results, and D represents the NRF2 nuclear translocation immunofluorescence detection results.

[0065] from Figure 6 The results showed that IL-1β stimulation significantly increased intracellular ROS; free quercetin reduced ROS levels, and the reduction was more pronounced after treatment with OQP NPs. Further Western blot and immunofluorescence assays revealed that OQP NPs promoted NRF2 nuclear translocation and restored HO-1 expression, suggesting that they can activate the endogenous antioxidant defense system of chondrocytes. These results indicate that OQP NPs not only exert antioxidant effects by releasing quercetin, but their ROS-responsive oxalate structure can also participate in the consumption of excess ROS, thus forming an antioxidant mechanism combining material response and drug action.

[0066] Example 6 OQP NPs inhibit iron overload and lipid peroxidation in chondrocytes: To evaluate the ability of OQP NPs to inhibit iron overload and lipid peroxidation in chondrocytes, ATDC5 chondrocytes from different treatment groups were subjected to the following experimental groupings and treatments: The normal control group was cultured in an equal volume of standard complete culture medium for 48 h; the IL-1β model group was treated with IL-1β at a final concentration of 10 ng / mL for 48 h; the free quercetin treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and free quercetin at a final concentration of 5 ng / mL for 48 h; and the OQP NPs treatment group was treated with both IL-1β at a final concentration of 10 ng / mL and OQP NPs at a final concentration of 5 ng / mL for 48 h. Subsequently, intracellular iron was detected using the FerroOrange fluorescent probe. 2+ The level of lipid peroxidation was detected using the BODIPY C11 probe, and the expression of ferroptosis-related antioxidant proteins SLC7A11 and GPX4 was detected by Western blot. Results are shown in [Figure number missing]. Figure 7 Where A is FerroOrange for detecting intracellular Fe 2+ The fluorescence images are shown in Figure B, which is the fluorescence image of lipid peroxidation detected by BODIPY C11, and Figures C and D are the Western blot and quantitative results of SLC7A11 and GPX4 proteins.

[0067] from Figure 7 It can be seen that after IL-1β stimulation, Fe in chondrocytes... 2+ Significant accumulation; Fe after treatment with free quercetin 2+ The level decreased, while the OQP NPs treatment group Fe 2+ Accumulation was further reduced. BODIPY C11 staining results showed that the IL-1β model group exhibited significantly enhanced oxidized green fluorescence and decreased non-oxidized red fluorescence, indicating a significant increase in cell membrane lipid peroxidation levels. Free quercetin could partially mitigate these changes, while OQP NPs treatment further reduced oxidized fluorescence, indicating a stronger inhibitory effect on lipid peroxidation. Western blot results showed that IL-1β stimulation significantly reduced SLC7A11 and GPX4 expression; OQP NPs significantly restored SLC7A11 and GPX4 expression, with a stronger effect than free quercetin. These results indicate that OQP NPs can reduce Fe... 2+ Abnormal accumulation, inhibition of lipid peroxidation, and restoration of the SLC7A11 / GPX4 antioxidant defense system, thereby inhibiting chondrocyte ferroptosis induced by the inflammatory environment.

[0068] Example 7 OQP NPs maintain mitochondrial homeostasis in chondrocytes: The ultrastructure of mitochondria in chondrocytes from different treatment groups (normal control group treated with routine culture; IL-1β model group treated with 10 ng / mL IL-1β; free quercetin group treated with 10 ng / mL IL-1β combined with 5 ng / mL quercetin; OQP NPs group treated with 10 ng / mL IL-1β combined with 5 ng / mL OQP NPs, all groups cultured for 48 h) was observed using transmission electron microscopy. Mitochondrial membrane potential was detected using the JC-1 fluorescent probe. Results are shown in [Figure number missing]. Figure 8 In the figure, A is a transmission electron microscope image of the ultrastructure of mitochondria in chondrocytes of different treatment groups, and B is a fluorescence image of mitochondrial membrane potential detected by JC-1.

[0069] from Figure 8 As can be seen, the mitochondrial structure of the normal control group cells was intact, and the mitochondrial cristae were clearly visible. After IL-1β stimulation, significant mitochondrial structural abnormalities appeared, manifested as changes in mitochondrial morphology, a reduction in cristae, and disordered arrangement. Free quercetin treatment could improve mitochondrial structure to some extent, while OQP NPs treatment resulted in more intact overall mitochondrial morphology and more pronounced preservation of mitochondrial cristae. JC-1 detection results showed that the control group exhibited predominantly red fluorescence formed by JC-1 aggregates, while IL-1β stimulation decreased red fluorescence and increased green fluorescence, indicating a decrease in mitochondrial membrane potential. After OQP NPs treatment, red fluorescence significantly recovered and green fluorescence decreased, indicating that OQP NPs could maintain mitochondrial membrane potential stability. These results suggest that OQP NPs can alleviate mitochondrial structural and functional damage caused by inflammation and oxidative stress, and further exert an anti-chondrocyte ferroptosis effect by maintaining mitochondrial homeostasis.

[0070] Example 8 The effect of OQP NPs on treating DMM-induced osteoarthritis in mice: A mouse model of osteoarthritis was established, with four subgroups: Sham, DMM, free quercetin, and OQP NPs. The medial meniscus destabilization (DMM) procedure was used to establish the mouse model. After anesthetizing the mice, the skin and joint capsule were incised on the medial side of the knee joint on the surgical side to expose and sever the medial meniscus and tibialis ligament, causing medial meniscus instability. The incision was then sutured layer by layer. In the Sham group, only the medial meniscus and tibialis ligament were exposed without severing; the remaining procedures were the same as in the DMM group. Intra-articular injection therapy began on the 7th postoperative day. During injection, the mouse knee joint was flexed, and a micro-injection needle was slowly inserted into the joint cavity of the surgical side knee joint through the patellar ligament. The injection volume was 10 μL each time, administered once every 7 days for 8 consecutive days. The treatments for each group were as follows: the Sham and DMM groups received an intra-articular injection of 10 μL of solvent as a control; the free quercetin treatment group received an intra-articular injection of 10 μL of free quercetin solution at a concentration of 5 μg / mL; and the OQPNPs treatment group received an intra-articular injection of 10 μL of OQP NPs dispersion at a concentration of 5 μg / mL. In other words, the dosage for both treatment groups was 0.05 μg / knee per administration. Free quercetin was prepared by first using a small amount of dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to the therapeutic concentration with sterile PBS, ensuring the final DMSO volume fraction was below 0.1%. OQP NPs were prepared as a uniform dispersion using sterile PBS. The Sham and DMM groups received the same volume of the corresponding solvent as the treatment groups to eliminate the influence of injection technique and solvent. After treatment, knee joints of mice in each group were collected for Micro-CT, histological staining, and immunohistochemical analysis. At the experimental endpoint, mouse knee joints were collected, and three-dimensional reconstruction was performed using Micro-CT. Quantitative analysis of subchondral bone parameters was conducted. Simultaneously, H&E staining and Safranin O / Fixed Green staining were used to evaluate histological changes in articular cartilage. Results are shown below. Figure 9 In the figure, A is the Micro-CT three-dimensional reconstruction image of the knee joint of each group of mice, B is the quantitative analysis results of parameters such as subchondral bone BV / TV (bone volume fraction), Tb.N (number of trabeculae), and Tb.Sp (trabeculae separation), and C is the H&E staining and Safranin O / Fixed Green staining image of the mouse knee joint.

[0071] Micro-CT results showed ( Figure 9 (Figure A) The joint structure in the Sham group was intact, and the articular surface was relatively smooth; the DMM group showed obvious joint structural damage and abnormal subchondral bone remodeling. Free quercetin could partially alleviate the above changes, while OQP NPs treatment resulted in more significant protection of the overall joint structure. Quantitative analysis results showed ( Figure 9(Figure B) After OQP NPs treatment, subchondral bone BV / TV and Tb.N increased, while Tb.Sp decreased, and the relevant parameters were closer to those of the Sham group. Histological staining showed ( Figure 9 (Figure C) The DMM group showed significant cartilage destruction, decreased cartilage thickness, and substantial loss of proteoglycans; free quercetin could partially improve cartilage degeneration, while the OQP NPs group had more intact cartilage structure and stronger Safranin O positive staining, indicating that OQP NPs can effectively reduce DMM-induced cartilage matrix loss and cartilage degeneration.

[0072] Example 9 Effects of OQP NPs on cartilage inflammation, matrix metabolism, and ferroptosis-related proteins in osteoarthritis: After the experiment in Example 8, mice in each group were sacrificed, and the surgically operated knee joint was completely dissected. Skin and surrounding excess muscle tissue were removed, preserving the joint capsule, distal femur, proximal tibia, and articular cartilage structures intact. The knee joint tissue was fixed in 4% paraformaldehyde solution at 4°C for 24–48 h. After washing with phosphate buffer, it was placed in 10% EDTA decalcification solution (pH 7.4) at room temperature for 3–4 weeks, with the decalcification solution changed every 2–3 days until complete decalcification. The decalcified tissue was rinsed with running water, dehydrated with a gradient of ethanol, cleared with xylene, and embedded in paraffin. Serial sections were prepared along the sagittal plane of the knee joint, with a section thickness of 5 μm. Sections from the same anatomical layer containing the medial femoral-tibial articular cartilage were selected for immunohistochemical staining. Paraffin sections were dewaxed with xylene and rehydrated with a gradient of ethanol. Antigen retrieval was performed according to the properties of the antigen to be tested. Endogenous peroxidase was blocked with 3% hydrogen peroxide solution, and non-specific binding sites were blocked with normal goat serum. Subsequently, primary antibodies against COL2A1, MMP13, iNOS, or GPX4 were added, diluted according to the antibody instructions, and incubated overnight at 4°C. After washing, the corresponding horseradish peroxidase-labeled secondary antibodies were added, and the mixture was incubated at room temperature. DAB staining was performed, and hematoxylin was used for counterstaining to detect the expression of MMP13, iNOS, COL2A1, and GPX4. Results are shown below. Figure 10 In this diagram, A shows the immunohistochemical staining patterns of MMP13, iNOS, COL2A1, and GPX4, and B shows the quantitative analysis results of the positive staining of the above proteins.

[0073] from Figure 10As can be seen, the expression of MMP13 and iNOS in the cartilage of the Sham group was low, while the expression of COL2A1 and GPX4 was high. The DMM group showed significantly increased MMP13 and iNOS, while COL2A1 and GPX4 were significantly decreased, suggesting enhanced inflammation, matrix degradation, and impaired ferroptosis-related antioxidant defense in osteoarthritic cartilage. Free quercetin could improve these changes to some extent, while OQP NPs treatment further reduced the positive expression of MMP13 and iNOS, and significantly increased the expression of COL2A1 and GPX4. These results further demonstrate that the OQP NPs of this invention can simultaneously reduce inflammatory responses, inhibit cartilage matrix degradation, and improve ferroptosis-related antioxidant defense in vivo, thereby delaying osteoarthritic cartilage degeneration.

[0074] Example 10 In vivo biosafety evaluation of OQP NPs: To evaluate the in vivo safety of OQP NPs, heart, liver, spleen, lung, and kidney tissues from mice in each group were collected after the animal experiment in Effect Example 8 and subjected to H&E staining. Serum was also collected to detect liver function, kidney function, and myocardial injury-related biochemical indicators. Results are shown in […]. Figure 11 and Figure 12 .

[0075] The results of H&E staining of major organs showed ( Figure 11 The structures of the heart, liver, spleen, lungs, and kidneys in each group were basically intact, with normal cell morphology and no obvious inflammatory cell infiltration, necrosis, or significant tissue structural abnormalities. Serum biochemical test results showed ( Figure 12 No significant abnormal changes were observed in indicators reflecting liver function, kidney function, and myocardial injury after OQP NPs treatment.

[0076] The above results demonstrate that the OQP NPs of the present invention do not produce significant systemic tissue toxicity while exerting a therapeutic effect on osteoarthritis, and have good in vivo biocompatibility.

[0077] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for preparing a ROS / pH dual-responsive quercetin self-framework nanomedicine based on an oxalyl chloride-responsive framework, characterized in that, Includes the following steps: Quercetin and a hydroxyl-containing hydrophilic polymer were added to a solvent and dissolved. A tertiary amine organic base was then added, and the mixture was placed under an inert atmosphere and low temperature. Oxaloyl chloride was then added to induce an esterification reaction between the oxalyl chloride and the hydroxyl groups in the quercetin and the hydroxyl-containing hydrophilic polymer, forming a reaction product with an oxalate ester linkage structure. After the reaction was completed, the product was purified and dried to obtain the ROS / pH dual-responsive quercetin self-framework nanomedicine.

2. The preparation method according to claim 1, characterized in that, The hydroxyl-containing hydrophilic polymer includes polyethylene glycol.

3. The preparation method according to claim 1, characterized in that, The tertiary amine organic bases include triethylamine.

4. According to the preparation method of claim 1, the amount of the hydroxyl-containing hydrophilic polymer used per 1 mmol of quercetin is 180-260 mg, the amount of the solvent is 20-40 mL, the amount of the tertiary amine organic base is 1-3 mL, and the amount of oxaloyl chloride is 0.08-0.18 mL.

5. The preparation method according to claim 1, characterized in that, The inert atmosphere includes a nitrogen atmosphere.

6. The preparation method according to claim 1, characterized in that, The esterification reaction takes 8–24 hours.

7. The preparation method according to claim 1, characterized in that, The purification process involves placing the reaction product in a medium with a molecular weight cutoff of 2000–8000 Da and dialysis using deionized water and ethanol as dialysis solvents.

8. The preparation method according to claim 7, characterized in that, The dialysis purification time is 24–72 h.

9. A ROS / pH dual-responsive quercetin self-framework nanomedicine prepared by the preparation method according to any one of claims 1 to 8.

10. The use of the ROS / pH dual-responsive quercetin self-framework nanomedicine of claim 9 as a medicament for the prevention and / or treatment of osteoarthritis.